CoChat

Interferon therapy and its association with depressive disorders – A review

Open access

The DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.

Abstract

Interferons (IFNs) are important in controlling the innate immune response to viral infections. Besides that, studies have found that IFNs also have antimicrobial, antiproliferative/antitumor and immunomodulatory effects. IFNs are divided into Type I, II and III. Type I IFNs, in particular IFN-α, is an approved treatment for hepatitis C. However, patients developed neuropsychological disorders during treatment. IFN-α induces proinflammatory cytokines, indoleamine 2,3-dioxygenase (IDO), oxidative and nitrative stress that intensifies the body’s inflammatory response in the treatment of chronic inflammatory disease. The severity of the immune response is related to behavioral changes in both animal models and humans. Reactive oxygen species (ROS) is important for synaptic plasticity and long-term potentiation (LTP) in the hippocampus. However, excess ROS will generate highly reactive free radicals which may lead to neuronal damage and neurodegeneration. The limbic system regulates memory and emotional response, damage of neurons in this region is correlated with mood disorders. Due to the drawbacks of the treatment, often patients will not complete the treatment sessions, and this affects their recovery process. However, with proper management, this could be avoided. This review briefly describes the different types of IFNs and its pharmacological and clinical usages and a focus on IFN-α and its implications on depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1048592

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The roles of neurotransmitters in IFN-induced mood dysregulation. IFN-α stimulates IDO1 activity, stimulating the conversion of tryptophan to kynurenine and affects the synthesis of serotonin. Through several pathway metabolisms, kynurenine will be converted to quinolinic acid and picolinic acid. Quinolinic acid decreases the level of IL-10 which has anti-inflammatory effects. The negative effects of quinolinic acid include increasing the levels of IFN-γ which causes inflammation. This inflammatory response result in the production of ROS and iNOS which decreases BH₄. This eventually reduces dopamine secretion. Quinolinic acid is an NMDA agonist and can cause neurotoxicity as seen in patients with Alzheimer’s disease, ALS and depression. Quinolinic acid could cause cellular apoptosis too through the increase in lipid peroxidation. *IDO1: Indoleamine 2,3-dioxygenase 1; IDO2: Indoleamine 2,3-dioxygenase 2; TDO2: tryptophan 2,3-dioxygenase; KYN: Kynurenine; NAD: Nicotinamide adenine dinucleotide; NMDA: N-methyl-D-aspartate; IL-10: Interleukin-10; IFN-γ: Interferon-gamma; IFN-α: Interferon-alpha; ROS: Reactive oxygen species; iNOS: Inducible nitric oxide synthase; GCH1: GTP cyclohydrolase I; BH₄: Tetrahydrobiopterin; KAT: Kynurenine aminotransferase.
Figure 1 The roles of neurotransmitters in IFN-induced mood dysregulation. IFN-α stimulates IDO1 activity, stimulating the conversion of tryptophan to kynurenine and affects the synthesis of serotonin. Through several pathway metabolisms, kynurenine will be converted to quinolinic acid and picolinic acid. Quinolinic acid decreases the level of IL-10 which has anti-inflammatory effects. The negative effects of quinolinic acid include increasing the levels of IFN-γ which causes inflammation. This inflammatory response result in the production of ROS and iNOS which decreases BH₄. This eventually reduces dopamine secretion. Quinolinic acid is an NMDA agonist and can cause neurotoxicity as seen in patients with Alzheimer’s disease, ALS and depression. Quinolinic acid could cause cellular apoptosis too through the increase in lipid peroxidation. *IDO1: Indoleamine 2,3-dioxygenase 1; IDO2: Indoleamine 2,3-dioxygenase 2; TDO2: tryptophan 2,3-dioxygenase; KYN: Kynurenine; NAD: Nicotinamide adenine dinucleotide; NMDA: N-methyl-D-aspartate; IL-10: Interleukin-10; IFN-γ: Interferon-gamma; IFN-α: Interferon-alpha; ROS: Reactive oxygen species; iNOS: Inducible nitric oxide synthase; GCH1: GTP cyclohydrolase I; BH₄: Tetrahydrobiopterin; KAT: Kynurenine aminotransferase.CC BY · PubMed Central
Figure 2 The effects of IFN-α therapy. IFN-α disrupts IDO1, SERT and possibly GCH1 systems and HPA axis leading to neurological changes and depression. Lower 5-HT production which is linked to depression is caused by the disruption on the SERT and IDO1 systems. IFN- also causes apoptosis, hippocampal atrophy and neurodegeneration via the KYN pathway as a result of increased IDO1 by (i) inhibiting the conversion of L-TRP, precursor of 5-HT (ii) production of QUIN which increases the stimulation of hippocampal NMDA (iii) production of 3-OH-KYN leading to increased ROS production causing intranucleosomal DNA damages and (iv) production of peripheral KYN which affects the CNS and subsequently neurodegeneration due to the release of neurotoxic metabolites. IFN- therapy also increases the production of pro-inflammatory cytokines which activate the HPA axis and causes depression. Another possible target of IFN-α is on GCH1 which reduces BH4 production, reducing 5-HT and leads to depression. IFN-α, Interferon-alpha; IL-1β, Interleukin-1beta; IFN-γ, Interferon-gamma; TNF-α, TNF-alpha; 5-HT, Serotonin; SERT, Serotonin transporter; IDO1, Indoleamine 2,3 dioxygenase; KYN, Kynurenine; 3-OH-KYN, 3-hydroxy-kynurenine; QUIN, Quinolinic acid; NMDA, N-methyl-D-aspartate; CNS, Central nervous system; ROS, Reactive oxygen species; BH₄, Tetrahydrobiopterin; CRH, Corticotropin-releasing hormone; HPA, Hypothalamic-pituitary-adrenal; GCH1, GTP cyclohydrolase I.
Figure 2 The effects of IFN-α therapy. IFN-α disrupts IDO1, SERT and possibly GCH1 systems and HPA axis leading to neurological changes and depression. Lower 5-HT production which is linked to depression is caused by the disruption on the SERT and IDO1 systems. IFN- also causes apoptosis, hippocampal atrophy and neurodegeneration via the KYN pathway as a result of increased IDO1 by (i) inhibiting the conversion of L-TRP, precursor of 5-HT (ii) production of QUIN which increases the stimulation of hippocampal NMDA (iii) production of 3-OH-KYN leading to increased ROS production causing intranucleosomal DNA damages and (iv) production of peripheral KYN which affects the CNS and subsequently neurodegeneration due to the release of neurotoxic metabolites. IFN- therapy also increases the production of pro-inflammatory cytokines which activate the HPA axis and causes depression. Another possible target of IFN-α is on GCH1 which reduces BH4 production, reducing 5-HT and leads to depression. IFN-α, Interferon-alpha; IL-1β, Interleukin-1beta; IFN-γ, Interferon-gamma; TNF-α, TNF-alpha; 5-HT, Serotonin; SERT, Serotonin transporter; IDO1, Indoleamine 2,3 dioxygenase; KYN, Kynurenine; 3-OH-KYN, 3-hydroxy-kynurenine; QUIN, Quinolinic acid; NMDA, N-methyl-D-aspartate; CNS, Central nervous system; ROS, Reactive oxygen species; BH₄, Tetrahydrobiopterin; CRH, Corticotropin-releasing hormone; HPA, Hypothalamic-pituitary-adrenal; GCH1, GTP cyclohydrolase I.CC BY · PubMed Central
Figure 3 Regulation of HPA axis by IFN-α. When stimulated by stress, cortisol is being released by the HPA axis. Cortisol has short term benefit whereby it could reduce inflammation. However, long term exposure could lead to irreversible change to the neuronal system and function which causes mood dysregulation. Constant stimulation of the HPA axis also could lead to depression because of increased stimulation on the amygdala, hippocampus and frontal cortex. CRH, Corticotropin-releasing hormone; ACTH, Adrenocorticotropic hormone.
Figure 3 Regulation of HPA axis by IFN-α. When stimulated by stress, cortisol is being released by the HPA axis. Cortisol has short term benefit whereby it could reduce inflammation. However, long term exposure could lead to irreversible change to the neuronal system and function which causes mood dysregulation. Constant stimulation of the HPA axis also could lead to depression because of increased stimulation on the amygdala, hippocampus and frontal cortex. CRH, Corticotropin-releasing hormone; ACTH, Adrenocorticotropic hormone.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Research works printed but not linked: 2

  1. Greenberg, 2000, ‘Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes’, Cancer, 89, 10.1002/1097-0142(20000715)89:2<356::aid-cncr21>3.0.co;2-z · doi:10.1002/1097-0142(20000715)89:2<356::aid-cncr21>3.0.co;2-z
  2. Thau, 2022, Physiology, cortisol

Cited by

See all 54

Metadata

Authors
Lai, J. Y., Ho, J. X., Kow, A. S. F., Liang, G., Tham, C. L., Ho, Y.-C., & Lee, M. T.
Affiliations
  • UCSI University (MY)
  • Universiti Putra Malaysia (MY)
  • I-Shou University (TW)
Corresponding author
  • Ho, Yu-Cheng
  • Lee, Ming Tatt
Venue
Frontiers in Immunology
Published
2023-02-22
Volume
14
Pages
1048592-1048592
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4321498954
Cited by
46
References
102
Citations by year
2026: 9 · 2025: 19 · 2024: 10 · 2023: 8
FWCI
0.89
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministry of Higher Education, Malaysia (FRGS/1/2021/WAB13/UCSI/02/1)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
interferon therapy, interferon-alpha, depressive disorders, hepatitis C treatment, neuropsychiatric adverse effects, oxidative stress, reactive oxygen species, neuroinflammation, indoleamine 2,3-dioxygenase, limbic system, medication adherence, mood disorders
MeSH terms
Animals, Depressive Disorder, Humans, Interferon Type I, Cytokines, Interferon-alpha, Reactive Oxygen Species

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interferon therapy and its association with depressive disorders – A review. https://app.cochat.ai/papers/10.3389/fimmu.2023.1048592
The paper
Lai, J. Y., Ho, J. X., Kow, A. S. F., Liang, G., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2023). Interferon therapy and its association with depressive disorders – A review. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1048592

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.